We are live on ! Find out more
ARRY

Array Biopharma Inc
ARRY

Delisted

ARRY was delisted on the 29th of July, 2019.

Back to rankings

268 hedge funds and large institutions have $5.5B invested in Array Biopharma Inc in 2019 Q1 according to their latest regulatory filings, with 62 funds opening new positions, 101 increasing their positions, 75 reducing their positions, and 29 closing their positions.

New
Increased
Maintained
Reduced
Closed

338% more call options, than puts

Call options by funds: $89.5M | Put options by funds: $20.4M

114% more first-time investments, than exits

New positions opened: 62 | Existing positions closed: 29

83% more capital invested

Capital invested by funds: $3B → $5.5B (+$2.5B)

44% more funds holding in top 10

Funds holding in top 10: 9 → 13 (+4)

35% more repeat investments, than reductions

Existing positions increased: 101 | Existing positions reduced: 75

14% more funds holding

Funds holding: 236 → 268 (+32)

Holders
268
Holders Change
+32
Holders Change %
+13.56%
% of All Funds
5.8%
Holding in Top 10
13
Holding in Top 10 Change
+4
Holding in Top 10 Change %
+44.44%
% of All Funds
0.28%
New
62
Increased
101
Reduced
75
Closed
29
Calls
$89.5M
Puts
$20.4M
Net Calls
+$69.1M
Net Calls Change
+$50.4M

Top Buyers

1
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
+$123M
2
PA
Perceptive Advisors
New York
+$88M
3
MWNA
Marshall Wace North America
New York
+$52.9M
4
ACA
Avoro Capital Advisors
New York
+$41.6M
5
1832 Asset Management
1832 Asset Management
Ontario, Canada
+$33.4M

Top Sellers

1
RG
Redmile Group
California
-$114M
2
Point72 Asset Management
Point72 Asset Management
Connecticut
-$84M
3
Millennium Management
Millennium Management
New York
-$30.8M
4
PAMU
Pictet Asset Management (UK)
United Kingdom
-$30.7M
5
BI
BVF Inc
California
-$27.6M
Name Holding Trade Value Shares
Change 		Change in
Stake
Victory Capital Management
226
Victory Capital Management
Texas
$71K – – –
APA
227
American Portfolios Advisors
New York
$66.2K -$6.25K -300 -10%
CAW
228
Cornerstone Advisors (Washington)
Washington
$54K +$12.8K +615 +38%
Daiwa Securities Group
229
Daiwa Securities Group
Japan
$34K +$6.22K +299 +27%
NFG
230
Next Financial Group
Texas
$32K – – –
NFH
231
NEXT Financial Holdings
Texas
$32K +$27.1K +1,300 New
EP
232
Elkfork Partners
Oregon
$31K +$17.7K +850 +208%
GRP
233
Global Retirement Partners
California
$30K +$2.6K +125 +11%
EI
234
Ellevest Inc
New York
$27K – – –
GHCM
235
Glen Harbor Capital Management
California
$25K +$14.6K +700 +208%
FHA
236
First Horizon Advisors
Tennessee
$24K +$5.29K +254 +33%
IWP
237
Icon Wealth Partners
Texas
$22K +$18.9K +908 New
AS
238
Altshuler Shaham
Israel
$21K +$17.6K +844 New
MCIM
239
Meadow Creek Investment Management
Georgia
$20K +$11.5K +550 +208%
AOWM
240
Alpha Omega Wealth Management
Virginia
$16K +$13.8K +661 New
LJHT
241
Laurie J. Hall Trustee
$15K – – –
SFSIG
242
San Francisco Sentry Investment Group
California
$14K – – –
FCM
243
Flinton Capital Management
Pennsylvania
$14K +$8.33K +400 +208%
TC
244
Truvestments Capital
Florida
$13K +$11.2K +537 New
JFA
245
JNBA Financial Advisors
Minnesota
$12K – – –
KPW
246
Kore Private Wealth
New York
$12K – – –
AC
247
Avestar Capital
New York
$12K +$3.96K +190 +58%
SWM
248
SeaCrest Wealth Management
New York
$12K +$4.16K +200 +67%
PA
249
Parallel Advisors
California
$12K +$8.33K +400 +400%
FPFS
250
First Personal Financial Services
North Carolina
$10K +$1.9K +91 +28%
8 9
10
11 12

ARRY Hedge Fund Activity: Q1 2019 in Review

268 of the 4,620 institutional investors tracked by Wall St. Rank reported a position in Array Biopharma Inc (ARRY) for Q1 2019, worth a combined $5.5B — up 83% from $3B a quarter earlier.

Buyers outnumbered sellers: 62 funds opened new ARRY positions and 29 closed out — a net gain of 33 holders — while 101 added to existing stakes and 75 trimmed.

The largest buyer was T. Rowe Price Associates, adding an estimated $123M. The largest seller was Redmile Group, cutting an estimated $114M.

  • 268 institutional investors held Array Biopharma Inc (ARRY) as of Q1 2019, up from 236 in Q4 2018.
  • Funds reported $5.5B of Array Biopharma Inc stock for Q1 2019, up 83% quarter-over-quarter.
  • 62 funds opened new Array Biopharma Inc positions in Q1 2019 and 29 closed out, a net change of +33 holders.
  • The largest Array Biopharma Inc buyer in Q1 2019 was T. Rowe Price Associates, an estimated $123M added.
  • The largest Array Biopharma Inc seller in Q1 2019 was Redmile Group, an estimated $114M sold.

Based on aggregated 13F filings for Q1 2019.